RxDoctor Payments Data

Beth Kirkpatrick, MD

Infectious Disease · Burlington, VTNPI 1033286216

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,500 of the $4,500 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Merck.

$4,500in general payments, 2019–2025

Across 1 payment — averaging $4500.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5K
$2,851,092in research payments, 2019–2025

Across 18 payments — averaging $158,394 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$2.9M

What the payments were for

  • Consulting fees$4,500100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$4,500

How this compares

Too few infectious disease providers in Vermontto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,527
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →